VTAK Key Statistics, Chart & Performance
The current stock price of VTAK is 2.01 USD. In the past month the price decreased by -15.55%. In the past year, price decreased by -80.04%.
VTAK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.89 | 215.95B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.27 | 199.22B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.11 | 140.40B | ||
| SYK | STRYKER CORP | 26.44 | 133.15B | ||
| BDX | BECTON DICKINSON AND CO | 13.52 | 55.64B | ||
| IDXX | IDEXX LABORATORIES INC | 53.13 | 53.50B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.2 | 49.52B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.04 | 37.73B | ||
| RMD | RESMED INC | 24.73 | 35.73B | ||
| DXCM | DEXCOM INC | 35.77 | 25.95B | ||
| PODD | INSULET CORP | 61.91 | 19.90B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.13 | 17.84B |
Related stock screener links
About VTAK
Company Profile
Catheter Precision, Inc. engages in the design, manufacture, and sale of medical devices and technologies for cardiac electrophysiology. The company is headquartered in Fort Mill, South Carolina and currently employs 22 full-time employees. The company went IPO on 2018-09-27. The firm is focused on developing technology for electrophysiology (EP) procedures by collaborating with physicians and continuously advancing its products. The firm's two primary products are the View into Ventricular Onset System (VIVO System) and LockeT. The VIVO System is a non-invasive imaging system that offers three-dimensional (3D) cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure. Its product portfolio also includes the Amigo Remote Catheter System. The company is developing technology for the treatment of acute decompensated heart failure.
Company Info
CATHETER PRECISION INC
1670 Highway 160 West, Suite 205
Fort Mill SOUTH CAROLINA US
Employees: 22
Phone: 19736912000
CATHETER PRECISION INC / VTAK FAQ
What does CATHETER PRECISION INC do?
Catheter Precision, Inc. engages in the design, manufacture, and sale of medical devices and technologies for cardiac electrophysiology. The company is headquartered in Fort Mill, South Carolina and currently employs 22 full-time employees. The company went IPO on 2018-09-27. The firm is focused on developing technology for electrophysiology (EP) procedures by collaborating with physicians and continuously advancing its products. The firm's two primary products are the View into Ventricular Onset System (VIVO System) and LockeT. The VIVO System is a non-invasive imaging system that offers three-dimensional (3D) cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure. Its product portfolio also includes the Amigo Remote Catheter System. The company is developing technology for the treatment of acute decompensated heart failure.
What is the current price of VTAK stock?
The current stock price of VTAK is 2.01 USD. The price increased by 9.84% in the last trading session.
What is the dividend status of CATHETER PRECISION INC?
VTAK does not pay a dividend.
What is the ChartMill technical and fundamental rating of VTAK stock?
VTAK has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of CATHETER PRECISION INC (VTAK) based on its PE ratio?
CATHETER PRECISION INC (VTAK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-73.84).
Would investing in CATHETER PRECISION INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VTAK.
VTAK Technical Analysis
VTAK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VTAK. VTAK has a bad profitability rating. Also its financial health evaluation is rather negative.
VTAK Financial Highlights
Over the last trailing twelve months VTAK reported a non-GAAP Earnings per Share(EPS) of -73.84. The EPS increased by 70% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -94.12% | ||
| ROE | -354.3% | ||
| Debt/Equity | 0 |
VTAK Forecast & Estimates
7 analysts have analysed VTAK and the average price target is 38.76 USD. This implies a price increase of 1828.36% is expected in the next year compared to the current price of 2.01.
For the next year, analysts expect an EPS growth of 96.27% and a revenue growth 533.33% for VTAK